ORIC stock holds firm as biotech valuation nears 0.93 billion USD

Published on 09/02/2026 at 13:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ORIC stock is trading in the lower teens in USD while its market capitalization stands just under 1.0 billion USD, highlighting how investors are valuing the biotech groups oncology pipeline as of early September 2026.

ORIC, US6862231085, Illustration mit AI erstellt.

ORIC Pharmaceuticals stock (ISIN US6862231085) is trading in the lower teens in USD as of September 2, 2026, with a market capitalization of about 0.93 billion USD according to market data, underlining how investors are currently valuing the oncology focused biotechnology company and its pipeline.

Market cap signals investor expectations

According to data compiled by Companies Marketcap, ORIC Pharmaceuticals carries a market capitalization of approximately 0.93 billion USD as of early September 2026, placing it firmly in the mid cap range within the United States biotechnology sector.

The same overview indicates that this valuation reflects a decline of 84.46% compared with a previously higher peak market capitalization, illustrating how sharply investor sentiment can adjust for emerging biopharma names when expectations are recalibrated.

Stock price in the lower teens in USD

On United States exchanges, ORIC stock is quoted around the lower teens in USD as of the last completed trading session before September 2, 2026, consistent with the valuation band signaled by the 0.93 billion USD market capitalization and indicating that each percentage move in the share price now translates into tens of millions of USD in changes to equity value.

For investors following the security via German trading venues, a quote page on Wallstreet Online shows that ORIC Pharmaceuticals shares traded at 11.43 EUR on August 28, 2026 on a German platform, with a 24 hour performance of minus 3.14%, giving euro based investors another lens on the recent price development.

Go deeper

More news and data on ORIC Pharmaceuticals

Stay on top of ORIC Pharmaceuticals developments, including ad hoc announcements and regulatory filings, by exploring the latest headlines in the ad hoc news topic overview.

All ORIC Pharmaceuticals news Investor Relations

Oncology pipeline as a value driver

ORIC Pharmaceuticals focuses on developing targeted oncology therapies, and the roughly 0.93 billion USD market capitalization as of early September 2026 suggests that investors are assigning significant option value to the companys pipeline despite the company still being in the development stage and therefore typically generating limited or no commercial product revenue at this point.

In this segment of the biotechnology market, valuation often hinges on expectations for future clinical milestones, partnership proceeds and potential licensing revenue, so the fact that ORIC stock trades in the lower teens per share while the market capitalization hovers near one billion USD highlights how the market is balancing risk and opportunity for this particular research portfolio.

Stock perspective for investors

With ORIC stock priced in the lower teens in USD as of the last completed trading session before September 2, 2026 and a market capitalization near 0.93 billion USD, the security remains a mid cap biotechnology name where each new data point from the pipeline can materially influence the share price.